Chemokines and inflammation in COPD: implications for targeted therapy
DOI:
https://doi.org/10.20883/medical.e1107Keywords:
chemokines, inflammation, targeted therapy, cytokines, pulmonary inflammation, immunomodulation, chronic obstructive pulmonary diseaseAbstract
A severe global health issue, chronic obstructive pulmonary disease (COPD) is characterised by recurrent respiratory symptoms and restricted breathing because of long-term lung inflammation. A class of minuscule cytokines known as chemokines is essential for immune cell recruitment and activation, which sustains the inflammatory response in COPD. This study thoroughly examines the origins, modes of action and effects of chemokines on developing COPD-related inflammation. We detail the involvement of key chemokines, such as CXCL9, CXCL10, and CXCL11, in COPD pathophysiology. These chemokines are integral in attracting neutrophils, macrophages, and T lymphocytes to the lungs, leading to chronic inflammation, airway remodelling, and emphysema. Increased levels of these chemokines correlate with increased disease severity and frequency of exacerbations. The review additionally examines the possibility of using chemokine pathway targeting as a treatment approach. Current COPD treatments primarily address symptoms without adequately controlling underlying inflammation. By inhibiting chemokine signalling, it may be possible to reduce inflammation, slow disease progression, and improve patient outcomes. We discuss various therapeutic approaches, including developing chemokine receptor inhibitors, biologics such as monoclonal antibodies, drug repurposing, and combination therapies with existing treatments.
Furthermore, we review ongoing and completed clinical trials investigating chemokine-targeted therapies in COPD, highlighting their efficacy and safety. This review also emphasises the need for further research to optimise these therapies and identify biomarkers for monitoring treatment response. In conclusion, chemokines are pivotal in the inflammatory processes of COPD. Targeting chemokine pathways presents a promising avenue for developing more effective treatments, which could significantly enhance patient care and disease management.
Downloads
References
Liu J, Ran Z, Wang F, Xin C, Xiong B, Song Z. Role of pulmonary microorganisms in the development of chronic obstructive pulmonary disease. Critical Reviews in Microbiology 2021;47:1–12. https://doi.org/10.1080/1040841X.2020.1830748.
Poot CC, Meijer E, Kruis AL, Smidt N, Chavannes NH, Honkoop PJ. Integrated disease management interventions for patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2021;2021. https://doi.org/10.1002/14651858.CD009437.pub3.
D’Anna SE, Maniscalco M, Cappello F, Carone M, Motta A, Balbi B, Ricciardolo FLM, Caramori G, Di Stefano A. Bacterial and viral infections and related inflammatory responses in chronic obstructive pulmonary disease. Annals of Medicine 2021;53:135–50. https://doi.org/10.1080/07853890.2020.1831050.
Korbecki J, Grochans S, Gutowska I, Barczak K, Baranowska-Bosiacka I. CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands. IJMS 2020;21:7619. https://doi.org/10.3390/ijms21207619.
Brandum EP, Jørgensen AS, Rosenkilde MM, Hjortø GM. Dendritic Cells and CCR7 Expression: An Important Factor for Autoimmune Diseases, Chronic Inflammation, and Cancer. IJMS 2021;22:8340. https://doi.org/10.3390/ijms22158340.
Kohli K, Pillarisetty VG, Kim TS. Key chemokines direct migration of immune cells in solid tumors. Cancer Gene Ther 2022;29:10–21. https://doi.org/10.1038/s41417-021-00303-x.
Ghafouri-Fard S, Honarmand K, Taheri M. A comprehensive review on the role of chemokines in the pathogenesis of multiple sclerosis. Metab Brain Dis 2021;36:375–406. https://doi.org/10.1007/s11011-020-00648-6.
Zinellu E, Zinellu A, Fois AG, Pau MC, Scano V, Piras B, Carru C, Pirina P. Oxidative Stress Biomarkers in Chronic Obstructive Pulmonary Disease Exacerbations: A Systematic Review. Antioxidants 2021;10:710. https://doi.org/10.3390/antiox10050710.
Korbecki J, Maruszewska A, Bosiacki M, Chlubek D, Baranowska-Bosiacka I. The Potential Importance of CXCL1 in the Physiological State and in Noncancer Diseases of the Cardiovascular System, Respiratory System and Skin. IJMS 2022;24:205. https://doi.org/10.3390/ijms24010205.
Inoue Y, Kaner RJ, Guiot J, Maher TM, Tomassetti S, Moiseev S, Kuwana M, Brown KK. Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype. Chest 2020;158:646–59. https://doi.org/10.1016/j.chest.2020.03.037.
Ermakov EA, Mednova IA, Boiko AS, Buneva VN, Ivanova SA. Chemokine Dysregulation and Neuroinflammation in Schizophrenia: A Systematic Review. IJMS 2023;24:2215. https://doi.org/10.3390/ijms24032215.
Wu X, Sun M, Yang Z, Lu C, Wang Q, Wang H, Deng C, Liu Y, Yang Y. The Roles of CCR9/CCL25 in Inflammation and Inflammation-Associated Diseases. Front Cell Dev Biol 2021;9:686548. https://doi.org/10.3389/fcell.2021.686548.
Ishida Y, Kuninaka Y, Mukaida N, Kondo T. Immune Mechanisms of Pulmonary Fibrosis with Bleomycin. IJMS 2023;24:3149. https://doi.org/10.3390/ijms24043149.
Sulfiana S, Iswanti FC. Chemokines in allergic asthma inflammation. Univ Med 2022;41:289–301. https://doi.org/10.18051/UnivMed.2022.v41.289-301.
Zhang S, Li G. Tumor expression of CXCL12 and survival of patients with colorectal cancer: A meta‑analysis. Oncol Lett 2022;24:436. https://doi.org/10.3892/ol.2022.13556.
Satarkar D, Patra C. Evolution, Expression and Functional Analysis of CXCR3 in Neuronal and Cardiovascular Diseases: A Narrative Review. Front Cell Dev Biol 2022;10:882017. https://doi.org/10.3389/fcell.2022.882017.
Karnati S, Seimetz M, Kleefeldt F, Sonawane A, Madhusudhan T, Bachhuka A, Kosanovic D, Weissmann N, Krüger K, Ergün S. Chronic Obstructive Pulmonary Disease and the Cardiovascular System: Vascular Repair and Regeneration as a Therapeutic Target. Front Cardiovasc Med 2021;8:649512. https://doi.org/10.3389/fcvm.2021.649512.
Cendrowicz E, Sas Z, Bremer E, Rygiel TP. The Role of Macrophages in Cancer Development and Therapy. Cancers 2021;13:1946. https://doi.org/10.3390/cancers13081946.
Dey S, Eapen MS, Chia C, Gaikwad AV, Wark PAB, Sohal SS. Pathogenesis, clinical features of asthma COPD overlap, and therapeutic modalities. American Journal of Physiology-Lung Cellular and Molecular Physiology 2022;322:L64–83. https://doi.org/10.1152/ajplung.00121.2021.
Halpin DMG, Criner GJ, Papi A, Singh D, Anzueto A, Martinez FJ, Agusti AA, Vogelmeier CF. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2021;203:24–36. https://doi.org/10.1164/rccm.202009-3533SO.
Ham J, Kim J, Ko YG, Kim HY. The Dynamic Contribution of Neutrophils in the Chronic Respiratory Diseases. Allergy Asthma Immunol Res 2022;14:361. https://doi.org/10.4168/aair.2022.14.4.361.
Dailah HG. Therapeutic Potential of Small Molecules Targeting Oxidative Stress in the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comprehensive Review. Molecules 2022;27:5542. https://doi.org/10.3390/molecules27175542.
Mishra RK, Ahmad A, Vyawahare A, Kumar A, Khan R. Understanding the Monoclonal Antibody Involvement in Targeting the Activation of Tumor Suppressor Genes. CTMC 2020;20:1810–23. https://doi.org/10.2174/1568026620666200616133814.
Zhou C, Gao Y, Ding P, Wu T, Ji G. The role of CXCL family members in different diseases. Cell Death Discov 2023;9:212. https://doi.org/10.1038/s41420-023-01524-9.
Calzetta L, Coppola A, Ritondo BL, Matino M, Chetta A, Rogliani P. The Impact of Muscarinic Receptor Antagonists on Airway Inflammation: A Systematic Review. COPD 2021;Volume 16:257–79. https://doi.org/10.2147/COPD.S285867.
Moradi S, Jarrahi E, Ahmadi A, Salimian J, Karimi M, Zarei A, Azimzadeh Jamalkandi S, Ghanei M. PI3K signalling in chronic obstructive pulmonary disease and opportunities for therapy. The Journal of Pathology 2021;254:505–18. https://doi.org/10.1002/path.5696.
Goonathilake MR, Waqar S, George S, Jean-Baptiste W, Yusuf Ali A, Inyang B, Koshy FS, George K, Poudel P, Chalasani R, Mohammed L. Can Phosphodiesterase 4 Inhibitor Therapy Be Used in Respiratory Diseases Other Than Chronic Obstructive Pulmonary Disease? Cureus 2022. https://doi.org/10.7759/cureus.27132.
Feng L, Lv X, Wang Y, Chu S, Dai Z, Jing H, Tong Z, Liao X, Liang L. Developments in smoking cessation interventions for patients with chronic obstructive pulmonary disease in the past 5 years: a scoping review. Expert Review of Respiratory Medicine 2022;16:749–64. https://doi.org/10.1080/17476348.2022.2108797.
Budnevsky AV, Avdeev SN, Ovsyannikov ES, Savushkina IA, Shkatova YaS, Shishkina VV. The role of mast cells in the pathogenesis of chronic obstructive pulmonary disease. Pul’monologiâ (Mosk) 2022;34:65–73. https://doi.org/10.18093/0869-0189-2022-3504.
Peng J, Yu Q, Fan S, Chen X, Tang R, Wang D, Qi D. High Blood Eosinophil and YKL-40 Levels, as Well as Low CXCL9 Levels, are Associated with Increased Readmission in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. COPD 2021;Volume 16:795–806. https://doi.org/10.2147/COPD.S294968.
Zhang W, Wang H, Sun M, Deng X, Wu X, Ma Y, Li M, Shuoa SM, You Q, Miao L. CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target. Cancer Communications 2020;40:69–80. https://doi.org/10.1002/cac2.12010.
Aldinucci D, Borghese C, Casagrande N. The CCL5/CCR5 Axis in Cancer Progression. Cancers 2020;12:1765. https://doi.org/10.3390/cancers12071765.
Files DC, Tacke F, O’Sullivan A, Dorr P, Ferguson WG, Powderly WG. Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19. PLoS Pathog 2022;18:e1010547. https://doi.org/10.1371/journal.ppat.1010547.
Mehta PP, Dhapte-Pawar VS. Repurposing drug molecules for new pulmonary therapeutic interventions. Drug Deliv and Transl Res 2021;11:1829–48. https://doi.org/10.1007/s13346-020-00874-6.
Bhat A, Ray B, Mahalakshmi AM, Tuladhar S, Nandakumar D, Srinivasan M, Essa MM, Chidambaram SB, Guillemin GJ, Sakharkar MK. Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders. Pharmacological Research 2020;160:105078. https://doi.org/10.1016/j.phrs.2020.105078.
Nomani H, Mohammadpour AH, Reiner Ž, Jamialahmadi T, Sahebkar A. Statin Therapy in Post-Operative Atrial Fibrillation: Focus on the Anti-Inflammatory Effects. JCDD 2021;8:24. https://doi.org/10.3390/jcdd8030024.
Heidary M, Ebrahimi Samangani A, Kargari A, Kiani Nejad A, Yashmi I, Motahar M, Taki E, Khoshnood S. Mechanism of action, resistance, synergism, and clinical implications of azithromycin. Clinical Laboratory Analysis 2022;36:e24427. https://doi.org/10.1002/jcla.24427.
Agache I, Beltran J, Akdis C, Akdis M, Canelo-Aybar C, Canonica GW, Casale T, Chivato T, Corren J, Del Giacco S, Eiwegger T, Firinu D, Gern JE, Hamelmann E, Hanania N, Mäkelä M, Hernández-Martín I, Nair P, O’Mahony L, Papadopoulos NG, Papi A, Park H, Pérez De Llano L, Posso M, Rocha C, Quirce S, Sastre J, Shamji M, Song Y, Steiner C, Schwarze J, Alonso-Coello P, Palomares O, Jutel M. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy 2020;75:1023–42. https://doi.org/10.1111/all.14221.
Nici L, Mammen MJ, Charbek E, Alexander PE, Au DH, Boyd CM, Criner GJ, Donaldson GC, Dreher M, Fan VS, Gershon AS, Han MK, Krishnan JA, Martinez FJ, Meek PM, Morgan M, Polkey MI, Puhan MA, Sadatsafavi M, Sin DD, Washko GR, Wedzicha JA, Aaron SD. Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020;201:e56–69. https://doi.org/10.1164/rccm.202003-0625ST.
Hurst JR, Gruffydd-Jones K, Biswas M, Guranlioglu D, Jenkins M, Stjepanovic N, Bamrara A. Efficacy and Safety of LAMA/LABA Fixed-Dose Combination Therapies in Chronic Obstructive Pulmonary Disease: A Systematic Review of Direct and Indirect Treatment Comparisons. COPD 2020;15:1529–43. https://doi.org/10.2147/COPD.S230955.
Calzetta L, Aiello M, Frizzelli A, Bertorelli G, Ritondo BL, Rogliani P, Chetta A. The Impact of Monoclonal Antibodies on Airway Smooth Muscle Contractility in Asthma: A Systematic Review. Biomedicines 2021;9:1281. https://doi.org/10.3390/biomedicines9091281.
Galluzzi L, Humeau J, Buqué A, Zitvogel L, Kroemer G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol 2020;17:725–41. https://doi.org/10.1038/s41571-020-0413-z.
Tashkin DP, Amin AN, Kerwin EM. Comparing Randomized Controlled Trials and Real-World Studies in Chronic Obstructive Pulmonary Disease Pharmacotherapy. COPD 2020;15:1225–43. https://doi.org/10.2147/COPD.S244942.
Singh D, Wedzicha JA, Siddiqui S, De La Hoz A, Xue W, Magnussen H, Miravitlles M, Chalmers JD, Calverley PMA. Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials. Respir Res 2020;21:240. https://doi.org/10.1186/s12931-020-01482-1.
Martin C, Burgel P-R, Roche N. Inhaled Dual Phosphodiesterase 3/4 Inhibitors for the Treatment of Patients with COPD: A Short Review. COPD 2021;Volume 16:2363–73. https://doi.org/10.2147/COPD.S226688.
Martinez FJ, Agusti A, Celli BR, Han MK, Allinson JP, Bhatt SP, Calverley P, Chotirmall SH, Chowdhury B, Darken P, Da Silva CA, Donaldson G, Dorinsky P, Dransfield M, Faner R, Halpin DM, Jones P, Krishnan JA, Locantore N, Martinez FD, Mullerova H, Price D, Rabe KF, Reisner C, Singh D, Vestbo J, Vogelmeier CF, Wise RA, Tal-Singer R, Wedzicha JA. Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre–Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward. Am J Respir Crit Care Med 2022;205:275–87. https://doi.org/10.1164/rccm.202107-1663SO.
Zhen G, Yingying L, Jingcheng D. Drug Therapies for COPD: A Bibliometric Review From 1980 to 2021. Front Pharmacol 2022;13:820086. https://doi.org/10.3389/fphar.2022.820086.
Iheanacho I, Zhang S, King D, Rizzo M, Ismaila AS. Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review. COPD 2020;15:439–60. https://doi.org/10.2147/COPD.S234942.
Che Man R, Sulaiman N, Ishak MF, Bt Hj Idrus R, Abdul Rahman MR, Yazid MD. The Effects of Pro-Inflammatory and Anti-Inflammatory Agents for the Suppression of Intimal Hyperplasia: An Evidence-Based Review. IJERPH 2020;17:7825. https://doi.org/10.3390/ijerph17217825.
Budnevsky AV, Avdeev SN, Ovsyannikov ES, Savushkina IA, Shkatova YaS, Shishkina VV. The role of mast cells in the pathogenesis of chronic obstructive pulmonary disease. Pul’monologiâ (Mosk) 2022;34:65–73. https://doi.org/10.18093/0869-0189-2022-3504.
Conlon T, John-Schuster G, Günes G, Jeridi A, Ertüz Z, Lehmann M, Costa R, Hu Y, Ciminieri C, Ansari M, Strunz M, Mayr C, Angelidis I, Verleden S, Gosens R, Eickelberg O, Schiller H, Königshoff M, Heikenwalder M, Yildirim AÖ. Therapeutic targeting of iBALT induces lung regeneration in COPD. 03.03 - Mechanisms of lung injury and repair, European Respiratory Society; 2021, p. 83. https://doi.org/10.1183/23120541.LSC-2021.83.
Keir HR, Richardson H, Fillmore C, Shoemark A, Lazaar AL, Miller BE, Tal-Singer R, Chalmers JD, Mohan D. CXCL-8-dependent and -independent neutrophil activation in COPD: experiences from a pilot study of the CXCR2 antagonist danirixin. ERJ Open Res 2020;6:00583–2020. https://doi.org/10.1183/23120541.00583-2020.
Kameda M, Otsuka M, Chiba H, Kuronuma K, Hasegawa T, Takahashi H, Takahashi H. CXCL9, CXCL10, and CXCL11; biomarkers of pulmonary inflammation associated with autoimmunity in patients with collagen vascular diseases–associated interstitial lung disease and interstitial pneumonia with autoimmune features. PLoS ONE 2020;15:e0241719. https://doi.org/10.1371/journal.pone.0241719.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 The copyright to the submitted manuscript is held by the Author, who grants the Journal of Medical Science (JMS) a nonexclusive licence to use, reproduce, and distribute the work, including for commercial purposes.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
